The market is estimated to grow at a CAGR of 7. 1% during 2020-2027. The E. coli testing market is growing primarily due to the rise in E. coli testing, growing product innovation, and rising research activities in the North America region.
New York, July 23, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "North America E. coli Testing Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Technology ; End User, and Country" - https://www.reportlinker.com/p05934834/?utm_source=GNW
However, the challenges in the E. coli testing damage the growth of the market. Additionally, increasing adoption of multiplex PCR technology and developments in biotechnology sector are likely to fuel the growth of the E. coli testing market during the forecast period.
Escherichia coli (E. coli) are rod-shaped gram-negative bacteria that are generally available in the food, environment, and intestines of warm-blooded animals. The majority of the E. coli strains are typically harmless to humans. Still, some strains are recognized to be the reason for serious some medical complications such as gastrointestinal tract infections, cholecystitis, cholangitis, neonatal meningitis, bacteremia, pneumonia, urinary tract infection (UTI) and regularly spread via polluted food or water.
The majority of instances of food poisoning and infectious diseases is caused due to E. coli. Therefore, it is essential to detect the concentration E. coli in various products. Apart from industrial sectors such as pharmaceutical, biotechnology, and environmental, the food & beverages sector is at a higher risk of E coli contamination. It is imperative for food & beverage companies to detect and monitor the presence of the bacteria before starting production, during the production process, and in the final products.
Similarly, various pharmaceutical and biotechnology companies follow good manufacturing practices (GMP), and current good manufacturing practices (cGMP). Rising incidences of infectious diseases are also leading to the diagnosis of E. coli in the samples collected from the patients. On average, adults in the United States have acute diarrhea once a year. Young children have it an average of twice a year. According to recent reports by the CDC, there were 11 multistate outbreaks of Shiga toxin-producing E. coli in the USA from 2011 to 2014 with six of them attributed to E. coli. Therefore, E. coli testing is widely performed across various countries, in turn, driving its market growth.
The outbreak of the COVID-19 pandemic has highly affected the North American region. The outbreak of pandemic has affected the E. coli testing market across the region. At present, the majority of the diagnostic laboratories and research institutes and centers are involved in diagnosing the COVID-19 and vaccines to treat the deadly virus. Thus, the shift of research centers and diagnostics laboratories towards the COVID19 pandemic has hindered the market growth. However, it is expected that the impact of the pandemic is likely to be seen for a few years. Also, the presence of various diagnostics and clinical laboratories offering E. coli testing is expected to contribute greatly during the forecast period.
In 2019, the monoclonal antibodies segment accounted for the largest share of the E. coli testing market. Monoclonal antibodies offer advantages such as low cross-reactivity, high specificity, and excellent lot-to-lot stability, which are likely to contribute to the dominancy of the segment during the forecast period.
A few of the significant secondary sources associated with the North America E. coli testing market report include World Health Organization (WHO), Centers of Disease Control and Prevention (CDC), OECD Health Statistics, and others.
Read the full report: https://www.reportlinker.com/p05934834/?utm_source=GNW
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001